
Publication
SBTi opens consultation on the Corporate Net-Zero Standard V2
On 18 March 2025, the Science-Based Targets initiative (SBTi) published an initial draft of its long-awaited “Corporate Net-Zero Standard V2” (Draft Standard).
Global | Publication | January 2019
The convergence of technology and life sciences was a defining feature of 2018. The boundaries of what defines the life sciences sector have increasingly blurred as life sciences companies look to the value of data in the search for innovation.
This does not mean, however, that “traditional” life sciences transactions are not going ahead. Some of the largest global deals have involved the acquisition of “traditional” research and development assets.
Case study
Norton Rose Fulbright advised on the sale of Acumyn Inc., a healthcare technology company, to a global Swedish health technology company, Elekta. This included negotiating Acumyn’s joint development and marketing agreement with Elekta, as well as acting on a number of complex mandates related to Acumyn’s technology and licensing with University Health Network, a leading Toronto based hospital network.
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Publication
On 18 March 2025, the Science-Based Targets initiative (SBTi) published an initial draft of its long-awaited “Corporate Net-Zero Standard V2” (Draft Standard).
Webinar
As crypto markets continue to evolve at an unprecedented pace, navigating the complex and ever-changing regulatory landscape is more crucial than ever.
Publication
Charlotte Hillyard, Senior Innovation Lawyer, will be a key speaker on the panel titled "Embracing GenAI Wave: Preparing Law Firms for the Future of Legal Innovation" at the Future Lawyers UK event on 1st April 2025.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025